Showing 1 - 5 results of 5 for search 'David Shrom', query time: 0.03s Refine Results
  1. 1
    Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial

    Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clini... by Andrew Blauvelt, Mark Lomaga, Russel Burge, Baojin Zhu, Wei Shen, David Shrom, Martin Dossenbach, Andreas Pinter

    Published 2020-02-01
    Get full text
    Article
  2. 2
    Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey

    Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey by Joseph F. Merola, David Shrom, Jennifer Eaton, Christine Dworkin, Craig Krebsbach, Bijal Shah-Manek, Julie Birt

    Published 2019-01-01
    Get full text
    Article
  3. 3
    Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey

    Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey by Joe Gorelick, David Shrom, Kiran Sikand, Lisa Renda, Russel Burge, Christine Dworkin, Craig Krebsbach, Ripsi P. Patel, Chitra Karki, David Rosmarin

    Published 2019-10-01
    Get full text
    Article
  4. 4
    Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

    Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis by Dafna D. Gladman, Ana-Maria Orbai, Uta Klitz, James Cheng-Chung Wei, Gaia Gallo, Julie Birt, Suchitrita Rathmann, David Shrom, Helena Marzo-Ortega

    Published 2019-01-01
    Get full text
    Article
  5. 5
    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

    Published 2020-03-01
    Get full text
    Article

Search Tools: